Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Hold” by Brokerages

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have received an average rating of “Hold” from the eight analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $17.60.

Several equities analysts recently issued reports on AMLX shares. The Goldman Sachs Group lifted their price objective on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th.

Insider Activity

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. purchased 100,000 shares of the stock in a transaction on Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now owns 858,571 shares in the company, valued at $1,888,856.20. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO James M. Frates acquired 40,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $2.53 per share, for a total transaction of $101,200.00. Following the completion of the transaction, the chief financial officer now owns 233,464 shares in the company, valued at approximately $590,663.92. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George M. Milne, Jr. bought 100,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $220,000.00. Following the completion of the purchase, the director now owns 858,571 shares in the company, valued at approximately $1,888,856.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its position in shares of Amylyx Pharmaceuticals by 52,575.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after purchasing an additional 15,247 shares during the period. Algert Global LLC purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $47,000. CWM LLC raised its holdings in shares of Amylyx Pharmaceuticals by 104.2% during the second quarter. CWM LLC now owns 28,643 shares of the company’s stock valued at $54,000 after acquiring an additional 14,613 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Amylyx Pharmaceuticals by 113.6% in the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock valued at $106,000 after acquiring an additional 29,697 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Amylyx Pharmaceuticals by 57.9% in the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after acquiring an additional 27,954 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $3.55 on Monday. The firm has a market cap of $241.42 million, a PE ratio of -3.32 and a beta of -0.55. The firm’s 50 day simple moving average is $2.52 and its 200-day simple moving average is $2.17. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same quarter in the prior year, the business posted $0.31 EPS. Equities research analysts predict that Amylyx Pharmaceuticals will post -2.27 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.